Agios Pharmaceuticals, Inc. or Galapagos NV: Who Manages SG&A Costs Better?

Who Manages SG&A Costs Better: Agios Pharmaceuticals or Galapagos NV?

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. From 2014 to 2023, Agios Pharmaceuticals and Galapagos NV have shown distinct trends in their SG&A expenditures. Agios Pharmaceuticals started with a modest $19 million in 2014, escalating to a peak of $149 million in 2020, before slightly decreasing to $120 million in 2023. In contrast, Galapagos NV began with $9 million in 2014, but their SG&A costs surged by over 2,500% to $239 million in 2022, before dropping to $94 million in 2023. This fluctuation highlights Galapagos NV's aggressive expansion strategy, while Agios Pharmaceuticals maintained a more consistent growth. Understanding these trends can provide valuable insights into each company's operational strategies and financial health.

Conclusion

While both companies have experienced significant changes in SG&A expenses, Agios Pharmaceuticals has managed a steadier trajectory, potentially indicating more controlled cost management.